Psychostimulant effect of levodopa: reversing sensitisation is possible.
Identifieur interne : 000795 ( PubMed/Corpus ); précédent : 000794; suivant : 000796Psychostimulant effect of levodopa: reversing sensitisation is possible.
Auteurs : Anna Castrioto ; Andrea Kistner ; Hélène Klinger ; Eugénie Lhommée ; Emmanuelle Schmitt ; Valérie Fraix ; Stephan Chabardès ; Patrick Mertens ; Jean-Louis Quesada ; Emmanuel Broussolle ; Pierre Pollak ; Stéphane C. Thobois ; Paul KrackSource :
- Journal of neurology, neurosurgery, and psychiatry [ 1468-330X ] ; 2013.
English descriptors
- KwdEn :
- Anxiety (chemically induced), Anxiety (complications), Basal Ganglia (drug effects), Deep Brain Stimulation (methods), Deep Brain Stimulation (psychology), Depression (chemically induced), Depression (complications), Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Dyskinesia, Drug-Induced (complications), Dyskinesia, Drug-Induced (therapy), Euphoria (drug effects), Female, Humans, Levodopa (adverse effects), Levodopa (pharmacology), Male, Middle Aged, Motivation (drug effects), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (therapy), Psychiatric Status Rating Scales (statistics & numerical data), Severity of Illness Index, Subthalamic Nucleus (physiology).
- MESH :
- chemical , adverse effects : Dopamine Agonists, Levodopa.
- chemically induced : Anxiety, Depression.
- complications : Anxiety, Depression, Dyskinesia, Drug-Induced, Parkinson Disease.
- drug effects : Basal Ganglia, Euphoria, Motivation.
- drug therapy : Parkinson Disease.
- methods : Deep Brain Stimulation.
- chemical , pharmacology : Levodopa.
- physiology : Subthalamic Nucleus.
- psychology : Deep Brain Stimulation.
- statistics & numerical data : Psychiatric Status Rating Scales.
- chemical , therapeutic use : Dopamine Agonists.
- therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- Female, Humans, Male, Middle Aged, Severity of Illness Index.
Abstract
Levodopa therapy in Parkinson's disease (PD) is associated with non-motor complications resulting from sensitisation of the ventral striatum system. Recent studies showed an improvement in non-motor complications in PD patients with subthalamic stimulation. We hypothesised that ventral striatum desensitisation might contribute to this improvement.
DOI: 10.1136/jnnp-2012-302444
PubMed: 22991345
Links to Exploration step
pubmed:22991345Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Psychostimulant effect of levodopa: reversing sensitisation is possible.</title><author><name sortKey="Castrioto, Anna" sort="Castrioto, Anna" uniqKey="Castrioto A" first="Anna" last="Castrioto">Anna Castrioto</name><affiliation><nlm:affiliation>Movement Disorder Unit, Pavillon de Neurologie, CHU Grenoble, Joseph Fourier University, Cedex 9, Grenoble 38043, France. acastrioto@chu-grenoble.fr</nlm:affiliation></affiliation></author><author><name sortKey="Kistner, Andrea" sort="Kistner, Andrea" uniqKey="Kistner A" first="Andrea" last="Kistner">Andrea Kistner</name></author><author><name sortKey="Klinger, Helene" sort="Klinger, Helene" uniqKey="Klinger H" first="Hélène" last="Klinger">Hélène Klinger</name></author><author><name sortKey="Lhommee, Eugenie" sort="Lhommee, Eugenie" uniqKey="Lhommee E" first="Eugénie" last="Lhommée">Eugénie Lhommée</name></author><author><name sortKey="Schmitt, Emmanuelle" sort="Schmitt, Emmanuelle" uniqKey="Schmitt E" first="Emmanuelle" last="Schmitt">Emmanuelle Schmitt</name></author><author><name sortKey="Fraix, Valerie" sort="Fraix, Valerie" uniqKey="Fraix V" first="Valérie" last="Fraix">Valérie Fraix</name></author><author><name sortKey="Chabardes, Stephan" sort="Chabardes, Stephan" uniqKey="Chabardes S" first="Stephan" last="Chabardès">Stephan Chabardès</name></author><author><name sortKey="Mertens, Patrick" sort="Mertens, Patrick" uniqKey="Mertens P" first="Patrick" last="Mertens">Patrick Mertens</name></author><author><name sortKey="Quesada, Jean Louis" sort="Quesada, Jean Louis" uniqKey="Quesada J" first="Jean-Louis" last="Quesada">Jean-Louis Quesada</name></author><author><name sortKey="Broussolle, Emmanuel" sort="Broussolle, Emmanuel" uniqKey="Broussolle E" first="Emmanuel" last="Broussolle">Emmanuel Broussolle</name></author><author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name></author><author><name sortKey="Thobois, Stephane C" sort="Thobois, Stephane C" uniqKey="Thobois S" first="Stéphane C" last="Thobois">Stéphane C. Thobois</name></author><author><name sortKey="Krack, Paul" sort="Krack, Paul" uniqKey="Krack P" first="Paul" last="Krack">Paul Krack</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:22991345</idno><idno type="pmid">22991345</idno><idno type="doi">10.1136/jnnp-2012-302444</idno><idno type="wicri:Area/PubMed/Corpus">000795</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000795</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Psychostimulant effect of levodopa: reversing sensitisation is possible.</title><author><name sortKey="Castrioto, Anna" sort="Castrioto, Anna" uniqKey="Castrioto A" first="Anna" last="Castrioto">Anna Castrioto</name><affiliation><nlm:affiliation>Movement Disorder Unit, Pavillon de Neurologie, CHU Grenoble, Joseph Fourier University, Cedex 9, Grenoble 38043, France. acastrioto@chu-grenoble.fr</nlm:affiliation></affiliation></author><author><name sortKey="Kistner, Andrea" sort="Kistner, Andrea" uniqKey="Kistner A" first="Andrea" last="Kistner">Andrea Kistner</name></author><author><name sortKey="Klinger, Helene" sort="Klinger, Helene" uniqKey="Klinger H" first="Hélène" last="Klinger">Hélène Klinger</name></author><author><name sortKey="Lhommee, Eugenie" sort="Lhommee, Eugenie" uniqKey="Lhommee E" first="Eugénie" last="Lhommée">Eugénie Lhommée</name></author><author><name sortKey="Schmitt, Emmanuelle" sort="Schmitt, Emmanuelle" uniqKey="Schmitt E" first="Emmanuelle" last="Schmitt">Emmanuelle Schmitt</name></author><author><name sortKey="Fraix, Valerie" sort="Fraix, Valerie" uniqKey="Fraix V" first="Valérie" last="Fraix">Valérie Fraix</name></author><author><name sortKey="Chabardes, Stephan" sort="Chabardes, Stephan" uniqKey="Chabardes S" first="Stephan" last="Chabardès">Stephan Chabardès</name></author><author><name sortKey="Mertens, Patrick" sort="Mertens, Patrick" uniqKey="Mertens P" first="Patrick" last="Mertens">Patrick Mertens</name></author><author><name sortKey="Quesada, Jean Louis" sort="Quesada, Jean Louis" uniqKey="Quesada J" first="Jean-Louis" last="Quesada">Jean-Louis Quesada</name></author><author><name sortKey="Broussolle, Emmanuel" sort="Broussolle, Emmanuel" uniqKey="Broussolle E" first="Emmanuel" last="Broussolle">Emmanuel Broussolle</name></author><author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name></author><author><name sortKey="Thobois, Stephane C" sort="Thobois, Stephane C" uniqKey="Thobois S" first="Stéphane C" last="Thobois">Stéphane C. Thobois</name></author><author><name sortKey="Krack, Paul" sort="Krack, Paul" uniqKey="Krack P" first="Paul" last="Krack">Paul Krack</name></author></analytic><series><title level="j">Journal of neurology, neurosurgery, and psychiatry</title><idno type="eISSN">1468-330X</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anxiety (chemically induced)</term><term>Anxiety (complications)</term><term>Basal Ganglia (drug effects)</term><term>Deep Brain Stimulation (methods)</term><term>Deep Brain Stimulation (psychology)</term><term>Depression (chemically induced)</term><term>Depression (complications)</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (therapeutic use)</term><term>Dyskinesia, Drug-Induced (complications)</term><term>Dyskinesia, Drug-Induced (therapy)</term><term>Euphoria (drug effects)</term><term>Female</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (pharmacology)</term><term>Male</term><term>Middle Aged</term><term>Motivation (drug effects)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (therapy)</term><term>Psychiatric Status Rating Scales (statistics & numerical data)</term><term>Severity of Illness Index</term><term>Subthalamic Nucleus (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Anxiety</term><term>Depression</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Anxiety</term><term>Depression</term><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Basal Ganglia</term><term>Euphoria</term><term>Motivation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Deep Brain Stimulation</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Deep Brain Stimulation</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Psychiatric Status Rating Scales</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa therapy in Parkinson's disease (PD) is associated with non-motor complications resulting from sensitisation of the ventral striatum system. Recent studies showed an improvement in non-motor complications in PD patients with subthalamic stimulation. We hypothesised that ventral striatum desensitisation might contribute to this improvement.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22991345</PMID><DateCreated><Year>2012</Year><Month>12</Month><Day>17</Day></DateCreated><DateCompleted><Year>2013</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J. Neurol. Neurosurg. Psychiatr.</ISOAbbreviation></Journal><ArticleTitle>Psychostimulant effect of levodopa: reversing sensitisation is possible.</ArticleTitle><Pagination><MedlinePgn>18-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2012-302444</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Levodopa therapy in Parkinson's disease (PD) is associated with non-motor complications resulting from sensitisation of the ventral striatum system. Recent studies showed an improvement in non-motor complications in PD patients with subthalamic stimulation. We hypothesised that ventral striatum desensitisation might contribute to this improvement.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Psychostimulant effects of levodopa were prospectively assessed in 36 PD patients with an acute levodopa challenge, before and 1 year after chronic subthalamic stimulation, using the Addiction Research Centre Inventory euphoria subscale. Postoperative evaluation was performed with the same dose of levodopa used in the preoperative assessment and after switching off stimulation. Preoperative and postoperative non-motor fluctuations in everyday life were investigated with the Ardouin Scale. Furthermore, in order to artificially reproduce non-motor fluctuations, a levodopa challenge keeping subthalamic stimulation on was performed to assess depression, anxiety and motivation before and after surgery under the different medication conditions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After 1 year of chronic subthalamic stimulation with 60.3% reduction in dopaminergic medication, the acute psychostimulant effects of levodopa were significantly reduced compared with preoperatively, as measured by the euphoria subscale (7.22 ± 4.75 vs 4.75 ± 5.68; p = 0.0110). On chronic subthalamic stimulation and with markedly reduced dopaminergic medication, non-motor fluctuations were significantly improved. While off medication/on stimulation scores of depression and anxiety were improved, in the on medication/on stimulation condition the motivation score worsened.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Acute psychostimulant effects of levodopa (off stimulation) were significantly reduced 1 year after surgery. These findings are likely due to desensitisation of the ventral striatum, allowed by the reduction of dopaminergic treatment, and the replacement of pulsatile treatment with continuous subthalamic stimulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castrioto</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Movement Disorder Unit, Pavillon de Neurologie, CHU Grenoble, Joseph Fourier University, Cedex 9, Grenoble 38043, France. acastrioto@chu-grenoble.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kistner</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Klinger</LastName><ForeName>Hélène</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lhommée</LastName><ForeName>Eugénie</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Schmitt</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Fraix</LastName><ForeName>Valérie</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Chabardès</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mertens</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Quesada</LastName><ForeName>Jean-Louis</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Broussolle</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pollak</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Thobois</LastName><ForeName>Stéphane C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Krack</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="N">Deep Brain Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005059" MajorTopicYN="N">Euphoria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020531" MajorTopicYN="N">Subthalamic Nucleus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22991345</ArticleId><ArticleId IdType="pii">jnnp-2012-302444</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2012-302444</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000795 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000795 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:22991345
|texte= Psychostimulant effect of levodopa: reversing sensitisation is possible.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:22991345" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |